



Date: 24 August 2017

Sydney, Australia

ASX Limited
20 Bridge Street
SYDNEY NSW 2000

ASX: NOX

Noxopharm Limited

ABN 50 608 966 123

Registered Office:

Suite 1 Level 6
50 Queen St
Melbourne VIC 3000
Australia

Operational Office:

Suite 3, Level 4
828 Pacific Highway
Gordon NSW 2072
Australia

Board of Directors

Mr Peter Marks

Chairman
Non-Executive
Director

Dr Graham Kelly

Chief Executive Officer
Managing Director

Dr Ian Dixon

Non-Executive
Director

NOXOPHARM RAISES \$5.5 MILLION TO ADVANCE CLINICAL PROGRAM

Noxopharm Limited (ASX: NOX) is pleased to announce the placement of 16,666,667 fully paid ordinary shares to sophisticated and institutional investors at a price of \$0.33 per share, raising a total of A\$5,500,000 (before costs).

Noxopharm has raised the funds to enable it to accelerate the clinical development of its front-line drug, NOX66, currently undergoing clinical trialing.

Commenting on the successful raising, CEO Dr Graham Kelly, said, "This raise comes on the back of growing confidence the Company has in NOX66 both in terms of safety and its anti-cancer effect."

"That confidence is driving us towards having the drug in a Phase 3 registration study by the end of 2018, with the ultimate objective of a revenue stream from a marketed product in 2022. These funds will go towards helping us meet that timetable."

"We also saw this as an opportunity to attract some cornerstone investors in the stock who share our long-term view of the potential of NOX66."

About the placement

Ordinary shares were offered to investors satisfying the requirements of either s708(8), 708(10) or 708(11) of the Corporations Act, and will be allocated as below:

- a) 8,149,525 of the Placement shares will be taken from the Company's 15% limit in accordance with ASX Listing Rule 7.1; and
- b) 8,517,142 of the Placement shares will be taken from the 10% additional placement capacity under ASX Listing Rule 7.1A.

APP Securities acted as lead manager for the Placement.

Settlement/quotation of the Placement shares is expected to occur on 31 August 2017.

About NOX66

NOX66 is an innovative dosage formulation of the experimental anti-cancer drug, idronoxil, developed specifically to preserve the anti-cancer activity of idronoxil in the body and to enhance its drug-like behaviour.

Idronoxil is a kinase inhibitor that works by inhibiting a range of enzymes including sphingosine kinase and PI3 kinase that regulate cell pro-survival mechanisms and which are over-expressed in cancer cells, as well as inhibiting external NADH oxidase Type 2 (ENOX 2) which is responsible for maintaining the transmembrane electron potential (TMEP) in the plasma membrane of cancer cells and whose expression is limited to cancer cells. Inhibition of these enzymes results in disruption of key downstream pro-survival mechanisms including resistance mechanisms, sensitizing the cancer cell to the cytotoxic effects of chemotherapy drugs and radiotherapy.

About Noxopharm

Noxopharm is an Australian drug development company with offices in Sydney, Melbourne and Hong Kong. The Company has a primary focus on the development of drugs to address the problem of drug-resistance in cancer cells, the major hurdle facing improved survival prospects for cancer patients. NOX66 is the first pipeline product, with later generation drug candidates under development. The Company also has initiated a pipeline of non-oncology drugs.

For further information, please contact:

Investor & Corporate Enquiries:

Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Company Secretary :

David Franks
T: +61 2 9299 9690
E: dfranks@fa.com.au

www.noxopharm.com